RxDoctor Payments Data

Charles Bolotte, MD

Family Medicine · Napoleonville, LANPI 1003884388

Payments from drug & device makers

$11,322in general payments, 2019–2025

Across 518 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AstraZeneca$1K
  • AbbVie$940
  • Novo Nordisk$765
  • Lilly USA, LLC$654
  • Takeda Pharmaceuticals U.S.A., Inc.$456
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$11,19299%
  • Education$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,322 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$161,954
Medicare patients
295
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide180$190,357
OzempicSemaglutide153$148,013
Repatha SureclickEvolocumab111$109,139
Repatha PushtronexEvolocumab78$99,150
JardianceEmpagliflozin131$98,337
FarxigaDapagliflozin Propanediol56$45,715
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$34,719
EliquisApixaban51$34,284
VascepaIcosapent Ethyl65$30,026
MyrbetriqMirabegron57$27,434
XareltoRivaroxaban19$15,444
TrulicityDulaglutide13$13,436
Breo ElliptaFluticasone/Vilanterol27$10,682
NexletolBempedoic Acid13$10,500
Icosapent Ethyl34$8,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25$654$209,044205 claims
Novo NordiskOzempic$765$148,013153 claims
Boehringer IngelheimJardiance$176$98,337131 claims
AstraZenecaFarxiga$1,488$45,71556 claims
GSKTrelegy Ellipta, Breo Ellipta$43$45,40177 claims
PfizerEliquis$331$34,28451 claims
Astellas Pharma US IncMyrbetriq$94$27,43457 claims
Johnson & JohnsonXarelto$51$15,44419 claims
MerckJanuvia, Steglatro, Janumet$35$13,05935 claims
Esperion Therapeutics, Inc.Nexletol$244$10,50013 claims
Arbor Pharmaceuticals, Inc.Edarbi$30$2,93312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Napoleonville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →